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Objectives The aim of the study was to evaluate early and late outcomes after percutaneous coronary intervention (PCI) of
unprotected left main coronary artery disease (ULMCA) and to compare bare-metal stent (BMS) and drug-eluting
stent (DES) subgroups.
Background PCI is an increasingly utilized method of revascularization in patients with ULMCA.
Methods This multicenter prospective registry included 252 patients after ULMCA stenting enrolled between March 1997
and February 2008. Non–ST-segment elevation acute coronary syndrome was diagnosed in 58% of patients; ST-
segment elevation myocardial infarction cases were excluded. Drug-eluting stents were implanted in 36.2% of
patients.
Results Major adverse cardiovascular and cerebral events (MACCE) occurred in 12 (4.8%) patients during the 30-day pe-
riod, which included 4 (1.5%) deaths. After 12 months there were 17 (12.1%) angiographically confirmed cases
of restenosis. During long-term follow-up (1 to 11 years, mean 3.8 years) there were 64 (25.4%) MACCE and 35
(13.9%) deaths. The 5- and 10-year survival rates were 78.1% and 68.9%, respectively. Despite differences in
demographical and clinical data in favor of BMS patients, unmatched analysis showed a significantly lower
MACCE rate in DES patients (25.9% vs. 14.9%, p  0.039). This difference was strengthened after propensity
score matching. The DES lowered both mortality and MACCE for distal ULMCA lesions when compared with BMS.
Ejection fraction 50% was the only independent risk factor influencing long-term survival.
Conclusions Stenting of ULMCA is feasible and offers good long-term outcome. Implantation of DES for ULMCA decreased
the risk of long-term MACCE, and particularly improved survival in patients with distal ULMCA disease. (J Am
Coll Cardiol 2009;54:1500–11) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.07.007(
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rnprotected left main coronary artery (ULMCA) disease
ccurs in 3% to 5% of patients with coronary artery disease
nd is the subject of intense investigation. Present guide-
ines consider this finding a major indication for coronary
rtery bypass grafting (CABG) (1) based mostly on the
ASS (Coronary Artery Surgery Study) (2) and ECSS
rom the *Medical University of Silesia, Katowice, Poland; †Upper-Silesian Heart
entre, Katowice, Poland; ‡American Heart of Poland, Ustron, Poland; §San
ntonio Endovascular and Heart Institute and University of Texas Health Science
enter at San Antonio, San Antonio, Texas; Cardiovascular Research Foundation,
ew York, New York; ¶American Heart of Poland, Dabrowa Gornicza, Poland; and
he #Thomas Jefferson University, Philadelphia, Pennsylvania.c
Manuscript received March 16, 2009; revised manuscript received July 7, 2009,
ccepted July 12, 2009.European Coronary Surgery Study) trials (3). These trials
howed that in comparison with medical therapy, CABG
mproves survival in patients with ULMCA during a 5-year
ollow-up period. However, these benefits diminish after
0- and 15-year follow-up with a mortality rate of over 50%
ith both treatment strategies (4–6).
See page 1512
On the other hand, recent studies suggest that percutaneous
oronary intervention (PCI) in this lesion subset is a feasible
lternative offering similar results when compared with surgical
evascularization (7,8). The use of bare-metal stents (BMS) in
omparison to balloon angioplasty has lowered the incidence of
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October 13, 2009:1500–11 The LE MANS Registry of Left Main Stentingbrupt vessel closure, whereas drug-eluting stents (DES) have
ignificantly decreased the risk of restenosis and major adverse
ardiovascular and cerebral events (MACCE) (7,9–11). As a
esult, after years of procedural improvements, left main
oronary artery (LM) stenting has been proven to be safe and
o offer a good midterm outcome. However, there are no data
oncerning longer (5- to 10-year) follow-up periods, espe-
ially with the use of DES.
Therefore, the aim of this study was to evaluate early and
ong-term results of ULMCA stenting with BMS and
ES, as well as to indicate independent risk factors influ-
ncing mortality and incidence of MACCE.
ethods
his is a prospective registry of 314 consecutive patients with
ignificant stenosis (50% diameter) of the LM treated with
tent implantation between January 1997 and March 2008 at
he Upper Silesian Heart Center, Katowice, and the 1st and
rd Department of American Heart of Poland in Ustron and
abrowa Gornicza, Poland.
We excluded patients with ST-segment elevation myo-
ardial infarction (n  20), completely occluded LM,
nd/or with at least 1 patent graft to the left anterior
escending or circumflex artery (n 42). Patients with both
ingle and multiple lesions in 1 to 3 vessels were included.
fter meeting inclusion/exclusion criteria, 252 patients
ualified for further analysis (Fig. 1).
The admission diagnosis was non–ST-segment acute
oronary syndrome (NSTE-ACS) in 152 (60.3%) patients
nd stable angina in 100 (39.7%) patients. Within the
STE-ACS group, 60 (39.4%) patients had non–ST-
egment elevation myocardial infarction and 92 (60.5%)
atients had unstable angina (Table 1).
The study population mean age was 68.5  12 years.
iabetes mellitus was present in 61 (24.2%) patients. Mean
ardiac surgery risk according to EuroSCORE (12) was 6
.8. Occurrence of distal LM stenosis was 59% (Table 1).
DES = 94
PCI
N = 252
LE MANS Registry
STEMIPatients with Significant LM Stenosis
Screened between 1997-2008
Protected LMCA
CABG
N = 1849
Randomization:
N = 105
PCI = 52  CABG = 53
BMS = 158
A Grant from the Polish Ministry of Science and Informatics No. 4P05B00819.
Figure 1 The LE MANS Study Algorithm
The LE MANS algorithm is from Buszman et al. (24) but is based on new data.
BMS  bare-metal stent(s); CABG  coronary artery bypass grafting; DES 
drug-eluting stent(s); LMCA  left main coronary artery; PCI  percutaneous
coronary intervention; STEMI  ST-segment elevation myocardial infarction. s
tPCI was a preferred strategy
ver CABG surgery because of
natomical suitability for PCI (n
88; 34.9%), high surgical risk
ccording to EuroSCORE of
ore than 6 (n  132; 52.4%),
r patient preference (n  32;
2.7%). Anatomical suitability
as defined as proximal and/or
haft noncalcified LM lesions
ith high vessel diameter (3.5
m). All decisions to withhold
rom CABG were based on con-
ensus between the surgeon and
nterventionalist.
ercutaneous revascularization.
n the majority of cases, direct
tenting was the preferred tech-
ique, except in critical and cal-
ified lesions, which were pre-
ilated with a small balloon (2.0
o 2.5 mm). For distal LM ste-
osis, stenting across the bifurca-
ion toward the left anterior de-
cending artery was performed
rst, followed by plain old balloon angioplasty and provi-
ional stenting of the circumflex artery with T-stenting or a
ulotte technique per operator preference. Post-dilation
ith kissing balloon angioplasty was consistently used to
omplete the distal LM stenting procedure (Table 2).
etween 1997 and 2001, exclusively BMS were used for all
ases. After that time, DES were recommended for the LM
ith a reference diameter 3.8 mm, and BMS were
mplanted if the LM reference diameter was 3.8 mm. In
emographic and Clinical Data,E MANS PCI (  252)Table 1 Demographic and Clinical Data,LE MANS PCI (n  252)
Male 173 (68.6%)
Age (yrs) 68.5 12
DM 61 (24.2%)
Arterial hypertension 193 (76.6%)
Hypercholesterolemia 145 (57.5%)
Smoking 105 (41.7%)
COPD 24 (9.5%)
Peripheral artery disease 63 (25%)
Previous MI 113 (44.8%)
Previous PCI 79 (31.3%)
Previous CABG 18 (7.1%)
LVEF (%) 48.6 7
NSTE-ACS 152 (60.3%)
Unstable angina 92 (60.5%)
NSTEMI 60 (39.4%)
EuroSCORE 6.0 2.8
ABG coronary artery bypass graft; COPD chronic obstructive pulmonary disease; DM diabetes
ellitus; LVEF  left ventricular ejection fraction; MI  myocardial infarction; NSTE-ACS  non–ST-
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
CABG  coronary artery
bypass grafting
CI  confidence interval
DES  drug-eluting stent(s)
LM  left main coronary
artery
LVEF  left ventricular
ejection fraction
MACCE  major adverse
cardiovascular and cerebral
event
NSTE-ACS  non–ST-
segment acute coronary
syndrome
OR  odds ratio
PCI  percutaneous
coronary intervention
TLR  target lesion
revascularization
ULMCA  unprotected left
main coronary arteryegment elevation acute coronary syndrome; NSTEMI non
ion; PCI  percutaneous coronary intervention.–ST-segment elevation myocardial infarc-
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The LE MANS Registry of Left Main Stenting October 13, 2009:1500–11otal, BMS were used in 158 patients and DES in 94
37.3%). Within the DES group, paclitaxel-eluting stents
ere used in 60 (63.8%) patients, whereas limus analogue-
luting stents were used in 34 (36.2%) patients (Table 2).
he results of baseline and post-procedure quantitative coro-
ary analysis are presented in Table 3.
An intra-aortic balloon pump was applied in 6.3% of
atients with complex LM lesion and significantly de-
ressed left ventricular function (left ventricular ejection
raction [LVEF] 30%). Intravenous glycoprotein IIb/IIIa
lockers (abciximab or eptifibatide) were administered in
4% of the cases. Unfractionated heparin was used during
he procedure to maintain an activated clotting time be-
ween 300 and 400 s or between 200 and 300 s for patients
reated with glycoprotein IIb/IIIa blockers.
ngiographic and Proceduralata, LE MANS PCI (n  252)Table 2 Angiog aphic and ProceduralData, LE MANS PCI (n  252)
Angiographic characteristics
Isolated LM 13 (5.6%)
LM with 1-vessel disease 51 (20.2%)
LM with 2-vessel disease 105 (41.6%)
LM with 3-vessel disease 83 (33%)
Distal LM involvement 149 (59%)
No. of diseased vessels 2 0.9
PCI data
Direct stenting of LM 204 (81%)
Stent length in LM (mm) 15.9 5.7
Stent diameter in LM (mm) 3.7 0.7
Distal LM stenting 149
POBA side branch 76 (51%)
T-stenting 30 (20.1%)
Culotte technique 43 (28.9%)
Kissing post-dilation of distal LM 149 (59%)
DES for LM 94 (37%)
PES 60 (63.8%)
LES 34 (36.2%)
BMS for LM 158 (63%)
Total no. of implanted stents 1.84 0.8
Complete revascularization 196 (78%)
MS  bare-metal stent(s); DES  drug-eluting stent(s); LES  limus-eluting stent(s); LM  left
ain coronary vessel; PES  paclitaxel-eluting stent(s); POBA  plain old balloon angioplasty;
ther abbreviations as in Table 1.
uantitative Coronary AnalysisTable 3 Quantitative Coronary Analysis
Baseline
Vessel reference (mm) 3.63 0.79
Baseline MLD (mm) 1.43 0.63
DS (%) 60.82 13.04
Lesion length (mm) 7.01 3.57
Post-procedure
Reference (mm) 3.92 0.73
MLD (mm) 3.43 0.86
DS (%) 9.22 6.977
alues are mean SD.
DS  diameter stenosis; MLD  minimal lumen diameter.Angiographic success was defined as LM residual stenosis
30%, minimal lumen diameter 3 mm, Thrombolysis In
yocardial Infarction flow grade 3, and no dissection.
he definition of clinical success included angiographic
uccess and death/myocardial infarct/stroke free in-hospital
utcome.
ntiplatelet regiment and concomitant pharmacological
reatment. Aspirin (300-mg initial dose, followed by 150
g daily) was ordered in all patients indefinitely. In the first
ohort of patients (treated between 1997 and 2001), ticlo-
idine was administered at least for 3 months, whereas in
he later group clopidogrel (300- to 600-mg initial dose and
30 Day Long Term
0%
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10%
15%
20%
25%
30%
Mortality
MACCE
1.6%
4.8%
25.4%
13.9%
MACCE Death MI Stroke TLR
 0%
 5%
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30%
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13.9%
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Figure 2 Early and Long-Term Results
for the Whole Study Group
(A) Mortality and major adverse cardiovascular and cerebral events (MACCE) at
30-day and long-term follow-up. (B) The incidence of MACCE, myocardial infarc-
tion (MI), stroke, and target lesion revascularization (TLR) at long-term
follow-up.5 mg daily after completion of the procedure) was main-
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October 13, 2009:1500–11 The LE MANS Registry of Left Main Stentingained for at least 12 months. The clopidogrel loading dose
as given to all patients before the procedure, except in
mergency cases, in which it was administered during or
ight after the intervention. After 1, 2, and beyond 2 years,
5.2%, 20.7%, and 16.6% of patients, respectively, were on
ouble antiplatelet therapy.
Other pharmacological treatments (e.g., statins, angiotensin-
onverting enzyme inhibitors, beta-blockers) were recom-
ended based on current practice and were left to the
iscretion of a supervising physician.
ollow-up. Six months after the index procedure, patients
ere scheduled for control coronary angiography. The
ong-term follow-up data (1 to 11 years, mean 3.8 years)
0 365 730 1095 1460 1825 2190
252      203      124       81       66         51       
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
C
u
m
u
la
tiv
e
 s
u
rv
iv
a
l
        1        2         3         4        5        6    
252   55 124   81   66    5
1 1 1 1 1 1 1
ime (days
0.4
0.5
0.6
0.7
0.8
0.9
1.0
C
um
ul
at
iv
e 
su
rv
iv
al
isolated LM, LM+1VD, LM+2VD 
isolated LM vs LM+1VD vs LM+2
0                2        3        4        5        6     
252    203    155    124      81     66       51
 

Figure 3 Kaplan-Meier Survival Curves
(A) Survival and major adverse cardiovascular and cerebral event-free (MACCE) su
study group. (B) Survival in subgroups with isolated left main (LM) and LM with 1-ere collected either by telephone through conversation
ith the patient or a relative, or during the ambulatory
isits. Information on any adverse event (including cardiac
nd noncardiac death, myocardial infarction, stroke, or
epeated revascularization) was confirmed with hospital
ischarge files where the adverse event took place and was
nalyzed by the Clinical Events Committee. The records of
eath were updated with the National Health System
egistry and Central Registry of Citizens. Eight patients
ere lost to follow-up.
tudy end points. The primary end point of this study was
he late incidence of any death in the whole study group;
ACCE in the whole study group and within the subgroup
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The LE MANS Registry of Left Main Stenting October 13, 2009:1500–11f patients with DES and BMS were considered secondary
tudy objectives.
A MACCE was defined as death of any cause, myocar-
ial infarction, stroke, target lesion revascularization (TLR),
r acute stent thrombosis. Death was considered either
ardiac or noncardiac. Deaths that could not be classified
ere considered cardiac. Myocardial infarction was defined
s elevation of total creatine kinase 3 times above the upper
imit of normal with a positive MB fraction. A TLR was
efined as any revascularization in the treated segment
ithin LM, or if distal LM was stented, in related proximal
egments of left anterior descending and circumflex arteries.
he incidence of stent thrombosis was evaluated in accor-
ance with the Academic Research Consortium Dentitions
f Stent Thrombosis (13).
afety and ethics. The study protocol was approved by the
thics Committee at the Medical University of Silesia. The
CI procedures were carried out by experienced interventional
ardiology teams in high-volume centers (more than 1,000
CIs per year in 1 center, with 300 interventions per operator)
ith cardiac surgery back-up on site or within 60 min of
mergency transportation. All interventionalists underwent
pecial training in LM stenting, based on the LE MANS
rotocol.
tatistical analysis. Parametric data were expressed as the
ean  SD, whereas nonparametric data were expressed as n
%). Group comparisons of parametric variables were per-
ormed using unpaired Student t tests. Nonparametric vari-
bles were compared using chi-square or Fisher exact tests. All
ests were 2-sided. Survival curves were estimated using
aplan-Meier analysis. Log-rank and Cox tests were per-
ormed for comparison of the survival curves between the
reatment arms.
Because of the nonrandomized nature of the study, a
ropensity score analysis was performed to adjust for differ-
nces in demographical and procedural data in groups
eceiving DES and BMS. A multiple logistic regression
Demographic, Clinical, and Procedural Data in DTable 4 Demographic, Clinical, and Procedu
DES (n 
Age (yrs) 64.0
Male 59 (62
DM 29 (30
Hypertension 74 (78
Hypercholesterolemia 56 (59
Smoking 40 (42
EuroSCORE (additive) 6.8
CCS classification 3.5
NSTE-ACS 65 (69
LVEF (%) 49.3
Distal LM involvement 68 (72
Stent diameter (mm) 3.4
No. of diseased vessels 2.1
No. of lesions except LM stenosis 1.5Values are mean  SD or n (%).
CCS  Canadian Cardiovascular Society; other abbreviations as in Table 2odel predicting DES assignment contained all covariate
ata categories. The resulting propensity scores were
atched using the nearest available Mahalanobis metric
atching within calipers (0.25  propensity score mean).
he resulting standardized difference was calculated for all
aseline covariates. The single risk factors influencing early
nd long-term survival were expressed as odds ratios (ORs)
ith 95% confidence intervals (CIs). The Cox proportional
azard model was used for multivariate analysis of indepen-
ent risk factors. All statistical analyses were performed
sing SAS version 9.1 (SAS Institute Inc., Cary, North
arolina), Statistica version 6.0 (Statsoft Inc., Tulsa, Oklahoma)
nd Matlab using MATLAB (R2008a, The Mathworks,
atick, Massachusetts).
esults
arly outcomes. Angiographic success was obtained in
8%, and clinical success was obtained in 95%. Within the
0-day period after the index procedure, MACCE were
bserved in 12 (4.8%) patients, including: 4 (1.6%) deaths,
(3.6%) myocardial infarcts, and 2 (0.8%) angiographically
onfirmed acute stent thromboses treated with balloon
ngioplasty (Fig. 2). Complete revascularization was ob-
ained in 60% of patients during the index procedure and in
n additional 18% in the second and third stage. The mean
ospitalization period was 7  5.8 days. The subacute stent
hromboses occurred in 1 case (0.4%).
The univariate analysis showed that LVEF 30% (OR:
1.8, 95% CI: 2.19 to 216, p  0.0002) and EuroSCORE
12 (OR: 30.8, 95% CI: 3.07 to 308) were the single risk
actors influencing early survival.
id-term and late outcomes. Based on a 12-month obser-
ation, 1-year total and MACCE-free survival were 92.8% and
1.5%, respectively. One hundred forty-one patients (56%)
nderwent control coronary angiography 6 to 12 months after
he index procedure, which detected 17 (12.1%) cases of
nd BMS Subgroupsata in DES and BMS Subgroups
BMS (n  158) p Value
65.1 10.8 0.45
114 (72.2) 0.10
32 (20.3) 0.06
119 (75.3) 0.59
89 (56.3) 0.70
65 (41.1) 0.97
5.6 3.8 0.01
3.3 0.9 0.14
86 (54.4) 0.04
48.4 12.9 0.61
81 (51.3) 0.001
3.7 1 0.01
2.0 0.9 0.43
1.4 1 0.4ES aral D
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October 13, 2009:1500–11 The LE MANS Registry of Left Main Stentingn-stent restenosis within the LM. For the vessels larger than
.8 mm, the restenosis rate was only 6.1%.
The mean long-term follow-up was 3.8 years (range 1 to
1 years, median 38.6 months). There were 35 deaths
13.9%), of which 28 (11%) were considered cardiac. A
ACCE occurred in 64 (25.4%) patients, which included
5 (9.9%) myocardial infarcts, 3 (1.2%) strokes, and 21
8.3%) TLRs (Fig. 2). According to Kaplan-Meier analysis,
he 5-year survival was 78.1% and the 10-year survival was
8.9% (Fig. 3A). According to the Academic Research
onsortium definition, there was 1 event of definite very
ate in-stent thrombosis in a patient with a DES, 2.5 years
fter the index procedure, while not on double antiplatelet
MACCE Death MI Stroke TLR
0%
5%
10%
15%
20%
25%
30%
DES
BMS
14.9%
25.9%
9.5%9.6%
13.3% 13.8%
1.3%1.1%
10.1%
3.2%
 
p = 0.04
 
NS
 
NS
 
NS
 
p = 0.037
Figure 4 Long-Term Unadjusted DES Versus BMS Results
Mortality and MACCE in DES and BMS groups.
Abbreviations as in Figures 1 and 2.
Demographic, Clinical, and Proceduralata in DES and BMS Subgroups After AdjustmTable 5 Demogr phic, Clini al, and ProceduData in DES and BMS Subgroups A
DES
(n  78)
Age (yrs) 64.5 10
Male 53 (67.9)
DM 22 (28.2)
Hypertension 62 (79.5)
Hypercholesterolemia 43 (55.1)
Smoking 31 (39.8)
EuroSCORE (additive) 6.4 3.7
CCS 3.4 0.9
NSTE-ACS 51 (65.4)
LVEF (%) 49.0 13
Distal LM involvement 58 (74.1)
Stent diameter (mm) 3.4 0.5
No. of diseased vessels 2.1 0.8
No. of lesions except LM stenosis 1.6 1Values are mean  SD or n (%).
Abbreviations as in Table 4.herapy. The rates of probable late and very late stent
hromboses were 3 (1.2%) and 5 (2%), respectively.
Survival of patients with isolated LM and LM with
ccompanying 1- to 3-vessel disease is shown in Figure 3B.
here was significantly better long-term survival in patients
ith isolated LM or LM with 1- and 2-vessel disease when
ompared with LM with 3-vessel disease (Cox p  0.02,
 0.005, p  0.008, respectively).
The univariate predictors of death were: age60 years (p
.03, OR: 2.48, 95% CI: 1.03 to 5.95), LVEF 50% (p 
.01, OR: 3.25, 95% CI: 1.45 to 7.27) and EuroSCORE on
dmission 9 (p  0.04, OR: 2.48, 95% CI: 1.1 to 4.56).
The Cox multivariate analysis for independent risk fac-
ors showed that LVEF 50% decreased survival rate,
hereas DES implantation decreased and stent diameter
3.8 mm increased the risk of MACCE.
ES versus BMS. Baseline clinical, lesion, and angio-
raphic data in DES and BMS subgroups are presented in
able 4. Patients receiving DES compared with BMS were
ore often diabetic (30.9% vs. 20.3%, p  0.06) and more
requently diagnosed with NSTE-ACS (69.1% vs. 54.4%,
 0.04). They had higher surgical risk according to
uroSCORE (6.8  3.9 vs. 5.6  3.8, p  0.01) and a
igher incidence of distal LM stenosis (72.3% vs. 51.3%,
 0.001). The mean DES diameter was lower than for
MS (3.4  0.5 mm vs. 3.7  1.0 mm, p  0.01).
Despite these differences in baseline characteristics, at
-year follow-up the unadjusted occurrence of MACCE
as significantly lower within the DES group (14.9% vs.
5.9%, p  0.039). There was a nonsignificant difference
avoring the DES group in mortality (DES vs. BMS:
.6% vs. 13.3%) and BMS in the risk of myocardial
nfarction (DES vs. BMS: 13.8% vs. 9.5%). The TLR
ate was significantly lower in the DES group (3.2% vs.
0.1%, p  0.04) (Fig. 4).
djustment
BMS
(n  78) p Value
Standardized
Difference (%)
64.1 11.6 0.81 3.9
54 (69.2) 0.86 2.8
20 (25.6) 0.72 5.8
64 (82.1) 0.68 6.5
48 (61.1) 0.45 12.1
33 (42.1) 0.76 4.8
6.6 3.8 0.82 3.7
3.4 0.8 1.00 0.0
47 (60.3) 0,7 10.6
48.2 13.2 0.70 6.2
57 (72.4) 0.82 3.7
3.5 0.8 0.82 3.7
2.1 0.7 0.89 2.2
1.6 1 0.84 3.2entral
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The LE MANS Registry of Left Main Stenting October 13, 2009:1500–11Propensity score matching of the demographical, clinical,
nd procedural data resulted in a bias reduction in 13 of 14
f our parameters and a standardized difference of 10% in
ll but 2 parameters (Table 5). The results after propensity
core adjustment were strengthened with higher significance
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Figure 5 Long-Term Adjusted DES Versus BMS Results
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.001), a higher number of diseased vessels (2.2  0.8 vs.
.8  1, p  0.0002), and more lesions (1.6  1 vs. 1.1 
.9, p  0.0006) in patients with distal LM disease.
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Figure 6 Long-Term Adjusted DES Versus BMS Results, Contin
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The LE MANS Registry of Left Main Stenting October 13, 2009:1500–11umber of men than women (79.0% vs. 66.2%, p  0.08)
n the BMS group and a trend toward higher Euro-
CORE (5.7  3.3 vs. 6.67  3.77, p  0.09) in the
ES cohort. In long-term follow-up, both survival and
ACCE–free survival rates were higher in favor of DES
or distal LM when compared with BMS (Fig. 8).
iscussion
his is the first prospective study presenting long-term
esults (up to 11 years) of unprotected LM stenting (LE
ANS registry). The early results of LM stenting with
igh procedural and clinical success (98% and 95%,
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espite the initial high risk profile of study population (Euro-
CORE 6, NSTE-ACS in 60% of patients).
Long-term mortality of 13.9% at 4 years and the 5- and
0-year survival of 78.1% and 68.9% are very satisfactory
nd compare favorably with survival presented in long-term
utcomes of coronary artery bypass surgery in the CASS
Coronary Artery Surgery Study) trial (2,15) and the Duke
niversity database (15). Angiographically confirmed reste-
osis occurred in 12.1% of patients. This result is compa-
able with those of studies involving only DES patients
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mplanted in vessels with reference diameter of 3.8 mm and
bove in which restenosis is relatively low (18), and in our
tudy was found in 6.1% of cases. Additionally, most of the
ES implanted in our study were paclitaxel-eluting stents,
hich in the ISAR LEFT MAIN (Intracoronary Stenting
nd Angiographic Results: Drug-Eluting Stents for Unpro-
ected Coronary Left Main Lesions) study showed a nu-
erically lower rate of restenosis and TLR when compared
ith sirolimus-eluting stents (16.0% vs. 19.4% and 13.6%
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Figure 8 Distal Left Main Cohort
(A) DES versus BMS survival. (B) The MACCE-free survival. Abbreviations as in Figs. 15.8%, respectively) (17). aThe analysis of the DES and BMS patient subgroups
howed a higher clinical and lesion characteristic risk profile
n patients treated with DES as evidenced by a higher
ncidence of diabetes mellitus and surgical risk according to
uroSCORE, higher number of patients with NSTE-
CS, and incidence of distal LM stenosis. Nonetheless, the
ong-term outcome was significantly better within the DES
roup, with lower MACCE (14.9% vs. 25.9%, p  0.04)
nd lower TLR (10.1% vs. 3.2%, p  0.037). Further
ropensity score matching and data adjustment confirmed
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The LE MANS Registry of Left Main Stenting October 13, 2009:1500–11The recorded difference in MACCE rate between DES
nd BMS is similar to the 6-month observation of Chieffo
t al. (7) and the 17-month observation of Valgimigli et al.
19) in the same period. However, after longer follow-up we
id not observe differences in mortality and incidence of
yocardial infarction between DES and BMS. The inci-
ence of adjusted TLR-free survival in both study groups is
imilar to that observed by Park et al. (10). There was 1 case
0.4% of the whole study group, 1% of the DES subgroup)
f definite very late in-stent thrombosis that occurred 2.5
ears after stent (DES) implantation. The incidence of this
vent is consistent with prior reports (20).
Contrary to reported data (21), there was no difference in
he survival and MACCE-free survival of patients with
nvolvement of distal LM, as opposed to proximal and/or
edial LM. This may be because of the higher number of
ES implanted within the distal LM compared with the
roximal/medial LM (45.6% vs. 24.7%, p  0.001). Hence,
e analyzed the outcome of patients with only distal LM
nvolvement. There was a significant decrease in mortality
nd MACCE in the patient subset who received DES when
ompared with BMS. This is the first study reporting
mproved survival after distal LM DES versus BMS. Con-
equently, based on these data, it is believed that the overall
ACCE risk decrease in patients receiving DES for
LMCA is mainly attributable to their high efficacy in
istal LM bifurcation. We believe that this should be the
tandard strategy for this lesion subset. On the other hand,
e observed reasonable long-term follow-up data in patients
ho received BMS for large (3.8 mm) LM vessels,
specially in the ostial or shaft portion. Nevertheless, data
rom Chieffo et al. (22) after DES implantation in this
esion subset with a TLR rate of 1% remain superior.
owever, it must be stressed that there are no DES with a
iameter larger than 4.5 mm. In these particular cases,
mplantation of BMS is acceptable.
Our 12-year experience with LM stenting reflects its
ontinuous progress. First, we showed significant reduction
f angina, significant improvement of the left ventricular
ystolic function, and preservation of exercise capacity in
ong-term follow-up (23). Second, we provided evidence for
he superiority of ULMCA stenting over CABG in terms of
estoring LVEF along with a trend for better survival (24).
n the current study, we show the safety and feasibility of
LMCA stenting with longest follow-up over a decade,
long with improved MACCE- and TLR-free survival with
ES in comparison with BMS. These findings support and
xtend the recent results of the SYNTAX (SYNergy be-
ween percutaneous coronary intervention with TAXus and
ardiac surgery) study (25), in which the patient subset with
M disease treated with DES had a similar overall
ACCE at 1-year follow-up to those treated with CABG.
e showed excellent long-term results of ULMCA stenting,
specially in patients with isolated LM disease or LM with 1-
nd 2-vessel coronary artery disease, in whom 10-year survival
as nearly 90% and was significantly better than in patientsith concomitant 3-vessel disease. In short follow-up, similar
rends were observed in the SYNTAX study.
tudy limitations. The rate of angiographic follow-up of
60% is relatively low, despite a recommendation for routine
ontrol. This was mainly related to more frequent use of DES
nd confidence in the method of LM stenting in later phase of
he study. Another study limitation was not routinely using
ntravascular ultrasound to check the acute result of the stenting.
onclusions
tenting of ULMCA is feasible and offers good late
utcomes. Isolated LM lesions or LM with 1- and 2-vessel
isease are associated with exceptional short- and long-term
utcomes, with the longest observation up to 11 years. A
ES implantation for ULMCA decreases the risk of
ong-term MACCE and particularly improves survival in
atients with distal ULMCA disease. These findings are
ncouraging and support the need for long-term follow-up
f patients with ULMCA randomized to DES or CABG in
arge trials.
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